- Home
- SIBN vs ORIC Comparison
SIBN vs ORIC Comparison
Compare SIBN & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIBN
- ORIC
- Stock Information
- Founded
- SIBN 2008
- ORIC 2014
- Country
- SIBN United States
- ORIC United States
- Employees
- SIBN N/A
- ORIC N/A
- Industry
- SIBN Medical/Dental Instruments
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- SIBN Health Care
- ORIC Health Care
- Exchange
- SIBN Nasdaq
- ORIC Nasdaq
- Market Cap
- SIBN 547.3M
- ORIC 545.5M
- IPO Year
- SIBN 2018
- ORIC 2020
- Fundamental
- Price
- SIBN $14.04
- ORIC $6.14
- Analyst Decision
- SIBN Strong Buy
- ORIC Strong Buy
- Analyst Count
- SIBN 6
- ORIC 9
- Target Price
- SIBN $24.50
- ORIC $18.43
- AVG Volume (30 Days)
- SIBN 370.2K
- ORIC 674.4K
- Earning Date
- SIBN 05-05-2025
- ORIC 05-05-2025
- Dividend Yield
- SIBN N/A
- ORIC N/A
- EPS Growth
- SIBN N/A
- ORIC N/A
- EPS
- SIBN N/A
- ORIC N/A
- Revenue
- SIBN $167,178,000.00
- ORIC N/A
- Revenue This Year
- SIBN $18.52
- ORIC N/A
- Revenue Next Year
- SIBN $16.36
- ORIC N/A
- P/E Ratio
- SIBN N/A
- ORIC N/A
- Revenue Growth
- SIBN 20.37
- ORIC N/A
- 52 Week Low
- SIBN $11.70
- ORIC $5.78
- 52 Week High
- SIBN $19.16
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- SIBN 33.41
- ORIC 34.15
- Support Level
- SIBN $13.80
- ORIC $5.78
- Resistance Level
- SIBN $15.40
- ORIC $8.11
- Average True Range (ATR)
- SIBN 0.58
- ORIC 0.54
- MACD
- SIBN -0.12
- ORIC -0.11
- Stochastic Oscillator
- SIBN 12.90
- ORIC 15.45
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.